<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336711</url>
  </required_header>
  <id_info>
    <org_study_id>2013/13MAR/117</org_study_id>
    <nct_id>NCT02336711</nct_id>
  </id_info>
  <brief_title>Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced SCC of the Oropharynx</brief_title>
  <official_title>Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced Squamous Cell Carcinoma of the Oropharynx: a Phase-I Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to assess the feasibility (i.e. early toxicity) of Molecular Imaging-based Dose
      Escalation in HPV Negative Patients With Locally Advanced SCC of the Oropharynx.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to assess the feasibility (i.e. early toxicity) of an adaptive dose
      escalation through 18F-FDG-PET-based dose painting by numbers in 10 HPV negative patients
      with locally advanced squamous cell carcinoma of the oropharynx. Treatment will be delivered
      with Helical Tomotherapy® or volumetric-modulated arc therapy (VMAT). Dose adaptation will be
      performed at 2 time-points with per-treatment 18F-FDG-PET/CT scans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>up to 3 months following the completion of radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary tumor control probability</measure>
    <time_frame>at 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>at 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dose escalation</intervention_name>
    <description>molecular imaging based radiotherapy dose escalation</description>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients with squamous cell carcinoma of the oropharynx, HPV-negative (p16 assay)

          -  T size of 3 cm or more in greatest dimension with the exclusion of tumor with bone
             infiltration

          -  N0, N1, N2a, N2b node (AJCC/UICC 7th edition)

          -  No distant metastasis

          -  No contra-indication to concomitant chemotherapy

          -  World Health Organization (WHO) Performance Status of 0 or 1 or Karnofsky performance
             status ≥ 80.

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Patients with induction chemotherapy will not be eligible

          -  Previous or concurrent history of cancer, except basal cell skin carcinoma

          -  Second primary tumor at the time of diagnosis

          -  Previous treatment with surgery, radiotherapy or chemotherapy for head and neck
             malignancy

          -  Any evidence of severe or uncontrolled systemic diseases (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic or renal disease), or psychological
             disorder

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Grégoire, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, and Center for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, St-Luc University Hospital, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Grégoire, MD, PhD</last_name>
    <phone>+ 32-2-7645431</phone>
    <email>vincent.gregoire@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Grégoire, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Nuyts, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

